U.S. patent application number 09/132231 was filed with the patent office on 2003-10-23 for method for producing novel dna sequences with biological activity.
Invention is credited to HORWITZ, MARSHALL S., LOEB, LAWRENCE A..
Application Number | 20030198950 09/132231 |
Document ID | / |
Family ID | 27493435 |
Filed Date | 2003-10-23 |
United States Patent
Application |
20030198950 |
Kind Code |
A1 |
HORWITZ, MARSHALL S. ; et
al. |
October 23, 2003 |
METHOD FOR PRODUCING NOVEL DNA SEQUENCES WITH BIOLOGICAL
ACTIVITY
Abstract
A method of obtaining an oligonucleotide capable of carrying out
a predetermined biological function. A heterogeneous pool of
oligonucleotides, x+y+z nucleotides in length, is first generated.
Each oligonucleotide has a 5' randomized sequence, x nucleotides in
length, a central preselected sequence, y nucleotides in length,
and a 3' randomized sequence, z nucleotides in length. The
resulting heterogeneous pool contains nucleic acid sequences
representing a random sampling of the 4.sup.x+z possible sequences
for oligonucleotides of the stated length. A random sampling of the
heterogeneous pool of oligonucleotides is introduced into a
population of cells that do not exhibit the predetermined
biological function. The population of engineered cells is then
screened for a subpopulation of cells exhibiting the predetermined
biological function. From that subpopulation of cells is isolated
an oligonucleotide containing the preselected sequence and capable
of carrying out the predetermined biological function.
Inventors: |
HORWITZ, MARSHALL S.;
(BELLEVUE, WA) ; LOEB, LAWRENCE A.; (BELLEVUE,
WA) |
Correspondence
Address: |
BURNS DOANE SWECKER & MATHIS L L P
POST OFFICE BOX 1404
ALEXANDRIA
VA
22313-1404
US
|
Family ID: |
27493435 |
Appl. No.: |
09/132231 |
Filed: |
August 11, 1998 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
09132231 |
Aug 11, 1998 |
|
|
|
08316415 |
Sep 30, 1994 |
|
|
|
5824469 |
|
|
|
|
08316415 |
Sep 30, 1994 |
|
|
|
08105108 |
Aug 11, 1993 |
|
|
|
08105108 |
Aug 11, 1993 |
|
|
|
07881607 |
May 12, 1992 |
|
|
|
07881607 |
May 12, 1992 |
|
|
|
07368674 |
Jun 19, 1989 |
|
|
|
07368674 |
Jun 19, 1989 |
|
|
|
06887070 |
Jul 17, 1986 |
|
|
|
Current U.S.
Class: |
435/6.12 ;
435/6.1; 435/91.2 |
Current CPC
Class: |
C07K 2319/02 20130101;
C12N 15/102 20130101; C12N 15/66 20130101; C12N 15/625 20130101;
C07K 2319/61 20130101; C12N 15/70 20130101; C12N 15/79 20130101;
C12N 15/74 20130101 |
Class at
Publication: |
435/6 ;
435/91.2 |
International
Class: |
C12Q 001/68; C12P
019/34 |
Goverment Interests
[0002] This invention was made with government support under Grant
OIG R35-CA39903, awarded by the National Cancer Institute. The
Government has certain rights in the invention.
Claims
The embodiments of the invention in which an exclusive property or
privilege is claimed are defined as follows:
1. A method of obtaining an oligonucleotide capable of carrying out
a predetermined biological function, comprising: (a) generating a
heterogeneous pool of oligonucleotides, x+y+z nucleotides length,
said oligonucleotides comprising a 5' randomized sequence, x
nucleotides in length, a central preselected sequence, y
nucleotides in length, and a 3' randomized sequence, a nucleotides
in length, said heterogeneous pool having nucleic acid se uences
representing a random sampling of the 4.sup.x+z possible sequences
for oligonucleotides of said length, (b) introducing a random
sampling of said heterogeneous pool of oligonucleotides into a
population of cells that do not exhibit the predetermined
biological function, (c) thereafter screening said population of
cells for a subpopulation of cells exhibiting said predetermined
biological function, and (d) isolating from said subpopulation of
cells an oligonucleotide comprising said preselected sequence and
capable of carrying out said predetermined biological function.
2. A method of obtaining an oligonucleotide capable of carrying out
a predetermined biological function, comprising: (a) generating a
heterogeneous pool of oligonucleotides, n nucleotides in length,
from a mixture of nucleotides consisting essentially of a% adenine,
t% thymidine, c% cytosine, and g% guanin wherein a+t+c+g=100%, said
heterogeneous pool having nucleic acid seque s representing a
random sampling of the .sub.4n possible sequences for
oligonucleotid of said length generated from nucleotides of said
relative percent concentrations, (b) introducing a random sampling
of said heterogeneous pool of oligonucleotides into a population of
cells that do not exhibit the predetermined biological function,
(c) thereafter screening said population of cells for a
subpopulation of cells exhibiting said predetermined biological
function, and (d) isolating from said subpopulation of cells an
oligonucleotide capable of carrying out said predetermined
biological function.
Description
[0001] This application is continuation-in-part of applicants'
copending application Ser. No. 06/887,070, filed Jul. 17, 1986.
FIELD OF THE INVENTION
[0003] This invention relates to a method for producing functional,
novel DNA sequences using biological selection of random nucleotide
sequences, and to the DNA sequences so produced.
BACKGROUND OF THE INVENTION
[0004] New methods to rearrange nucleotide sequences in DNA have
enriched our understanding of how protein structure governs
function. By monitoring the effects of particular substitutions on
structure and activity one can explore putative catalytic
mechanisms. The most direct approach is to select the region of a
gene that codes for the active site of an enzyme and systematically
substitute nucleotides based on a knowledge of the amino acid
groups, the mechanism for catalysis, and three dimensional
structure. This approach has been applied to diverse enzymes
including: trypsin (Craik, et al., 1985; see the appended
citations), lysozyme (Perry & Wetzel, 1984), and
.beta.-lactamase (Dalbadie-McFarland, et al., 1986) with
considerable success. We demonstrate here an alternative strategy.
Instead of making precise substitution based on detailed knowledge
of structure and function, one can insert into genes stretches of
nucleotides containing random sequences and use biological
selection to obtain new proteins harboring a spectrum of
substitutions.
[0005] In our initial studies on the selection of nucleotide
sequences from random populations, we examined the -35 region of
the promoter of the gene for tetracycline resistance (HorWitz &
Loeb, 1986; 1988b). We obtained 85 new active promoters, many of
which bore little resemblance to the promoter consensus sequence
and some of which were more active than the consensus sequence or
the wild type tetracycline promoter. We have now remodeled the gene
coding for .beta.-lactamase, by replacing DNA at the active site
with random nucleotide sequences, and have selected functional
active site mutants having altered catalytic activities.
SUMMARY OF THE INVENTION
[0006] The invention provides, in one embodiment, a method of
obtaining an oligonucleotide capable of carrying out a
predetermined biological function. A heterogeneous pool of
oligonucleotides, x+y+z nucleotides in length, is first generated.
Each oligonucleotide has a 5' randomized sequence, x nucleotides in
length, a central preselected sequence, y nucleotides in length,
and a 3' randomized sequence, z nucleotides in length. The
resulting heterogeneous pool contains nucleic acid sequences
representing a random sampling of the 4.sup.x+z possible sequences
for oligonucleotides of the stated length. A random sampling of the
heterogeneous pool of oligonucleotides is introduced into a
population of cells that do not exhibit the predetermined
biological function. The population of engineered cells is then
screened for a subpopulation of cells exhibiting the predetermined
biological function. From that subpopulation of cells is isolated
an oligonucleotide containing the preselected sequence and capable
of carrying out the predetermined biological function.
[0007] In a related embodiment, the heterogeneous pool of
oligonucleotides may be generated from a biased mixture of
nucleotides. The heterogeneous pool of oligonucleotides, n
nucleotides in length, is synthesized from a mixture of nucleotides
consisting essentially of a % adenine, t % thymidine, c % cytosine,
and g % guanine, wherein a+t+c+g=100%. The resulting heterogeneous
pool contains nucleid acid sequences representing a random sampling
of the 4.sup.n possible sequences for oligonucleotides of the
stated length generated from nucleotides of the stated relative
concentrations. A random sampling of the heterogeneous pool of
oligonucleotides is introduced into a population of cells that do
not exhibit the predetermined biological function. The population
of engineered cells is screened for a subpopulation of cells
exhibiting the predetermined biological function, and from the
subpopulation of cells an oligonucleotide capable of carrying out
the predetermined biological function is isolated.
BRIEF DESCRIPTION OF THE DRAWINGS
[0008] The details of typical embodiments of the present invention
will be described in connection with the accompanying drawings in
which:
[0009] FIG. 1 presents a schematic overview of the representative
synthesis, transformation, and selection steps described in Example
1;
[0010] FIG. 2 is an RNA gel blot analysis quantifying tetracycline
resistance gene transcription in various plasmid populations
described in the Examples;
[0011] FIG. 3 shows the substitutions made in the wild type
promoter sequence for the tetracycline resistance gene, as
described in Examples 1 through and summarized in the Discussion
following Example 5;
[0012] FIG. 4 shows the construction of plasmid pBDL, as described
in Example 8;
[0013] FIG. 5 illustrates the overall scheme for the insertion of
oligonucleotides containing random DNA inserts described in Example
8, with (A) Step I showing construction of the nonproducer strain
pBNP, and (B) Step II showing replacement of the oligonucleotide in
the nonproducer strain with random DNA sequences, wherein
amp=ampicillin, tet=tetracycline, and n=unspecified bases; and
[0014] FIG. 6 shows the active site sequence substitutions obtained
as described in Example 8, including the determined nucleotide
sequence of each of the carbenicillin resistant mutants, and the
deduced amino acid sequences.
DETAILED DESCRIPTION OF THE INVENTION
[0015] The invention provides methods for producing novel,
functional DNA sequences using biological selection. To carry out
the present invention, a library of all possible DNA sequences is
used to transform, transfect or infect suitable, competent host
cells. Biological selection is used to isolate functional DNA
sequences exhibiting a desired biological activity. The process of
the invention is set forth in greater detail in the description and
examples that follow.
[0016] Synthesis of random DNA sequences. DNA sequences in the form
of oligonucleotides can be readily synthesized using various
procedures, including phosphoramidite synthesis or phosphotriester
chemistry, as described, e.g., in Oligonucleotide Synthesis: A
Practical Approach, Gait, Ed., IRL Press, Oxford, England (1984),
incorporated by reference herein, or may be obtained already
synthesized from a commercial source. Synthesis of oligonucleotides
has been greatly simplified by automation. Once synthesized, the
DNA may be retrieved and purified using techniques, individually or
in combination, such as gel electrophoresis, high performance
liquid chromatography or thin layer chromatography. A mixed
population of oligonucleotides, heterogeneous and random in DNA
sequence, may also be produced using these methods. Individual
oligonucleotides of lengths up to several hundred basepairs can
then be hybridized to one another to construct DNA duplexes for
mutagenesis.
[0017] In the present invention, the number of possible replacement
DNA sequences generated for a given DNA sequence will depend on the
number of randomly substituted nucleotide bases in the synthetic
oligonucleotides synthesized. For example, for a population of
random DNA oligonucleotides, each 19 basepairs in length, there
exists a maximum of 4.sup.19 (3.times.10.sup.11) different possible
replacement sequences (combinations of nucleotide bases).
[0018] Cloning of the random DNA sequences. The random DNA
sequences synthesized as described above are used to transform
prokaryotic or eukaryotic cells. The DNA may be introduced using
cloning vectors including plasmids, vectors capable of integrating
into host cell chromosomes, for example, bacteriophage lambda,
other bacteriophages (e.g., the M13 family of filamentous
bacteriophage vectors described by Messing (in Methods in
Enzymology, 101, pp. 20-78, Academic Press (1983)), viruses, or
cosmids, or by vectorless gene transfer wherein linearized DNA
containing the gene of interest is added directly to a culture of
host cells, resulting in transformation of the cells. Glover, D.
M., in Gene Cloning: The Mechanics of DNA Manipulation, London,
Chapman and Hall (1984). Other methods of introducing DNA into a
cell may also be used, for example, direct injection such as
microinjection, or using sperm carriers.
[0019] Insertion of random DNA sequences. Where a vector is used as
the cloning vehicle, the vector chosen may be altered by deleting a
particular region of DNA known to contain a functional site, for
example, the promoter recognition site for a particular gene, using
standard methods, such as cleavage by restriction enzymes, to
insert the synthetic random DNA sequences. The termini of random
DNA sequences, synthesized as described above, may be modified so
as to be easily inserted into the vector selected. For example,
sequences with "sticky" ends generated by cleavage by restriction
enzymes may be inserted into a vector which has been digested using
the same enzymes. The random DNA sequences are then inserted into
the vector with a ligation enzyme, for example, the enzyme T4 DNA
ligase, using standard techniques such as those described by
Maniatis, et al., in Molecular Cloning: A Laboratory Manual, Cold
Spring Harbor, N.Y. (1982), incorporated by reference herein.
[0020] The random DNA sequences may also be directly inserted into
a vector without removing any DNA, for example, to select for DNA
sequences encoding a novel protein. Random sequences may thus be
introduced into an open reading frame (a DNA sequence encoding a
protein and containing appropriate regulatory elements for
translation including a promoter, ribosome binding site,
translation initiation codon, and stop codon) by ligating the
random fragments to the appropriate genetic regulatory elements,
such as transcription and translation initiators, for example the
promoter, or Shine-Dalgarno ribosome binding site.
[0021] Expression of recombinant DNA. The recombinant DNA vectors
containing the inserted randomly synthesized DNA sequences are then
used to transform or transfect suitable host cells such as
bacteria. An example of a suitable bacterium is E. coli. If E. coli
bacteria are used as a host, a preferred method for transformation
is the high efficiency technique described by Hanahan, J. Mol.
Biol., 166, pp. 557-580 (1983), incorporated by reference herein.
Host cells are then grown in an antibiotic, such as ampicillin, to
select for those cells which contain recombinant plasmids carrying
the cointroduced random DNA sequences.
[0022] The recombinant DNA may then be purified from host cell
preparations and sequenced using well-known procedures to verify
that it contains the inserted synthetic DNA sequences, and to
reveal the sequence of the inserts.
[0023] Biological selection. The methods of the present invention
use biological selection of randomly synthesized DNA sequences to
identify and isolate those sequences that exhibit a desired
biological function. To accomplish such selection, a procedure for
detecting the desired functional activity must be chosen. In
Examples 1-5 below, the function selected for is the ability to
promote transcription of the gene for tetracycline resistance. In
these examples, the antibiotic tetracycline is used to select for
those synthetic DNA sequences able to function as promoters for
transcription of the tetracycline resistance gene, as determined by
the ability of E. coli cells carrying plasmids to grow in the
presence of the antibiotic.
[0024] Novel DNA sequences capable of a different function, for
example "leader" sequences (also known as "signal sequences"), may
also be selected from a population of random DNA fragments. Leader
sequences allow for the transmembrane insertion or extracellular
secretion of cellular proteins, and are common to both prokaryotes
and eukaryotes. Leader sequences from different proteins are
composed predominately of hydrophobic amino acid residues and range
in length from 13 to 36 amino acid residues. Alberts, B. M., et
al., in Molecular Biology of the Cell, New York, Garland
Publishing, Inc., (1983). While a consensus leader sequence has
been established for several proteins (Kretsinger, R. H. &
Creutz, C. E., Nature, 320 p. 573 (1986)), the leader sequences of
most proteins differ considerably and contain no homology to each
other, (von Heijne, G., J. Mol. Biol., 184 pp. 99-105 (1985)),
suggesting that a great variety of protein sequences may possess
this secretory function. Leader sequences may be identified, e.g.,
by using a gene for a secreted protein, such as .beta.-lactamase,
capable of conferring positive growth selection. .beta.-lactamase
is secreted extracellularly and protects cells from attack by
antibiotics, such as ampicillin (Alberts et al., supra). The 5'
portion of the .beta.-lactamase gene of the plasmid pBR322 contains
66 nucleotides coding for a 23 amino acid residue leader sequence
of the protein product. Ambler, R. P. & Scott, G. K., Proc.
Nat'l. Acad. Sci. (USA), 75, pp. 3732-3736 (1978); and Sutcliffe,
J. G. Proc. Nat'l Acad. Sci. (USA), 75, pp. 3737-3741 (1978).
Frameshift mutations, point substitutions, and deletion mutations
in this region of the gene produce defective proteins that are not
secreted from the cell. Koshland, D. A Genetic Analysis of
Beta-lactamase, Ph.D. thesis, Mass. Inst. Technol., Cambridge
(1982). Consequently, bacteria harboring plasmids with
nonfunctional mutations in the leader sequence of the
.beta.-lactamase gene are sensitive to the antibiotic ampicillin,
whereas bacteria harboring plasmids with intact .beta.-lactamase
genes are resistant to ampicillin. As a result, host cells
containing vectors with inserted DNA sequences not capable of
functioning as .beta.-lactamase leader sequences will not survive
in media containing the antibiotic ampicillin. However, cells which
do secrete .beta.-lactamase and survive in media containing the
antibiotic will contain vectors having synthetic DNA sequences
capable of functioning as leader sequences, and these sequences may
then be readily isolated and sequenced as described above.
[0025] In addition, growth selection using the present invention
may be used to select DNA sequences capable of encoding novel
proteins. Random DNA sequences may contain unique sequences that
are capable of coding for biologically active proteins. Thus, long,
random DNA fragments may be ligated into a vector such as a plasmid
vector containing the regulatory elements for gene expression,
including DNA encoding promoter and ribosome binding sites. The
resulting vector will thus be able to transcribe random proteins
from the randomly generated open reading frame. A heterogeneous
population of plasmids, each coding for a unique, random protein
may be used to transform appropriate eukaryotic or prokaryotic host
cells such as E. coli cells. From these cells, proteins possessing
novel catalytic activity may be identified using growth selection.
Alternately, to isolate a novel protein capable of degrading a
particular plastic, the transformants may be grown on media, for
example, Luria-Bertani (LB) agar, covered with the particular
plastic as a growth barrier, and then layered with more media
(e.g., LB agar). Bacterial clones containing random DNA sequences
conveying plastic-degrading activity will penetrate the plastic
barrier to grow in the topmost layer of agar. An example of the use
of this invention to select DNA sequences encoding novel proteins
from a population of random DNA sequences is described below, in
Example 7.
[0026] From the foregoing, it can be appreciated that the
biological selection of the present invention provides a technique
for screening large numbers of random, synthetic DNA sequences to
identify those novel sequences capable of carrying out the chosen
function. The present invention does not require characterization
(e.g., sequencing, hybridization, and other procedures) of the
synthesized DNA sequences prior to the selection process, thereby
eliminating the need for tedious and time-consuming
manipulations.
[0027] Other parameters useful for biological selection based on
the ability of transformed cells to grow in certain media, in
addition to antibiotic resistance, include resistance to toxins
such as metals and environmental pollutants such as polychlorinated
biphenyl (PCB), and the ability to grow in media containing or
lacking specific metabolites, for example, in the presence of
unusual carbon sources including oils and environmental
pollutants.
[0028] The present invention may also be used to select for novel,
synthetic DNA sequences capable of encoding a peptide which
exhibits the biological activity of the peptide encoded by the
natural (wild-type) DNA sequences, or for entirely new, functional
peptides. Standard assays may be used to detect the presence or
absence of expressed peptide in a growth medium or even within the
host cells. For example, visually screenable assays to indicate the
presence of a peptide using enzyme and enzyme substrate reactions
to generate a color signal, such as the blue color produced by
.beta.-galactosidase in the presence of sugar analogs, may be used.
The expressed peptide must then be tested for the ability to carry
out the function of the corresponding wild-type DNA peptide or to
determine whether a peptide exhibiting the new function has been
produced.
[0029] Examples 1 through 5 below, describe representative
protocols for obtaining novel, synthetic DNA sequences with
promoter activity. A comparison of known RNA polymerase-binding
sites of different genes of E. coli reveals two highly conserved
promoter elements centered at about 10 and 35 nucleotide basepairs
upstream from the start of transcription. Pribnow, J. Mol. Biol.,
99, pp. 419-443 (1975); Schaller et al., P.N.A.S. USA, 72, pp.
737-741 (1975); Takanami, et al., Nature, 260, pp. 297-302 (1976);
Seeburg, et al., Eur. J. Biochem., 74, pp. 107-113 (1977); and
Rosenberg and Court, Ann. Rev. Genet, 13, pp. 319-353 (1979). The
involvement of each nucleotide in the initiation of transcription
has been inferred largely from an analysis of mutations. Rare
mutations that increase transcription (so-called "up" mutations)
usually increase homology with the consensus sequence and spacing,
while the more common mutations that decrease transcription ("down"
mutations) usually decrease homology with the consensus sequence
and spacing. McClure, supra. Nevertheless, as demonstrated by the
present invention, sequences that greatly differ from the consensus
sequence can still function as promoters.
[0030] The present invention uses random mutagenesis to produce
novel, synthetic DNA sequences which are capable of exhibiting
biological activity, although such sequences may substantially
deviate from known, wild-type sequences having that same function
in nature. The process described above and in the Examples which
follow, extends beyond the use of mutagenesis merely as a tool to
study the nature of regions of DNA encoding specific biological
activity. The present invention uses significantly expanded random
mutagenesis, i.e., heterogeneity, at a substantial number of
nucleotide bases within a DNA sequence, to produce novel,
functional sequences. Furthermore, the use of selection pressure,
e.g., binding a preselected antigen, provides an efficient,
cost-effective and rapid means for screening large numbers of
synthetic DNA sequences to isolate those novel DNA sequences
capable of, e.g., coding for an immunological variable region of
desired specificity.
[0031] In summary, the invention provides a method of obtaining an
oligonucleotide capable of carrying out a predetermined biological
function. First, a heterogeneous pool of oligonucleotides is
generated. The oligonucleotides are typically n nucleotides in
length, and the nucleic acid sequences of the oligonucleotides in
the heterogeneous pool typically represent a random sampling of the
4.sup.n possible sequences for oligonucleotides of that length. A
random sampling of the heterogeneous pool of oligonucleotides is
introduced into a population of cells that do not exhibit the
predetermined biological activity. The population of cells is
thereafter screened for a subpopulation of engineered cells that
does exhibit the predetermined biological function. From the
subpopulation of cells, an oligonucleotide capable of carrying out
the predetermined biological function is isolated.
[0032] In the practice of the invention, the randomized
oligonucleotide can range in length (n) from about 3 or more (or 1
codon or more, if the oligonucleotide is to be expressed) to
several hundred or more nucleotides in length. It is generally
preferable to limit the size of the randomized oligonucleotide to
about 24 bases, coding for 8 amino acids, as this will potentially
produce a heterogeneous pool of about 8.sup.20 or a billion
different oligonucleotides, which is convenient for screening.
[0033] The randomized oligonucleotide may alternatively include
first and second randomized regions (x and z nucleotides in length,
respectively) that flank on either side a linker region (y
nucleotides in length) of preselected sequence. The heterogeneous
pool of these tripartite oligonucleotides represents a random
sampling of the 4.sup.x+z possible sequences of such
oligonucleotides of that length (x+y+z). A random sampling of this
heterogeneous pool of oligonucleotides is in turn introduced into a
population of cells that do not exhibit the predetermined
biological function. The population of cells is thereafter screened
for a subpopulation of cells exhibiting the predetermined
biological function. That is, the functionality of the tripartite
oligonucleotides is screened as a unit. From the selected
subpopulation of cells, an oligonucleotide containing the linker
sequence and capable of carrying out the predetermined biological
function is isolated. Representative protocols are set forth in
Example 8 below. The linker sequence can correspond with a native
sequence or can be a novel sequence that is present by design in
all of the randomized oligonucleotides. For example, a codon for
serine in a native sequence can be changed in a preselected manner
to a codon for another nucleophilic amino acid, such as
cysteine.
[0034] In this embodiment, the overall length of the randomized
portion of the oligonucleotide (x+z) is preferably held to no more
than about 24 bases. The individual and relative lengths of the
flanking randomized and central conserved sequences are not
critical and may be dictated by site-specific considerations, such
as a previously observed association of the linker sequence with
the screened function.
[0035] As described above, the nucleotide composition of the
randomized oligonucleotide region(s) may alternatively be biased in
favor of or away from any of adenine, thymidine, cytosine, and/or
guanine. Such biasing is conveniently accomplished by adjusting the
relative concentrations of the dNTPs from which the
oligonucleotides are randomly synthesized. In other words, the
relative concentrations of A, T, C, and G need not be about 25%
each, e.g., A may constitute a%; T, t%; C, c%; and G, g%; provided
that a+t+c+g=100%. The resulting heterogeneous pool of
oligonucleotides, n nucleotides in length, will nevertheless have
nucleic acid sequences representing a random sampling of the
4.sup.n possible sequences for oligonucleotides of that length
synthesized from a pool of nucleotides having such preadjusted
relative concentrations.
[0036] The following Examples are presented to illustrate the
present invention and to assist one of ordinary skill in making and
using the same. The examples are not intended in any way to
otherwise limit the scope of the disclosure or the protection
granted by the Letters Patent hereon.
EXAMPLE 1
Production of Novel DNA Sequences With Promoter Activity
[0037] In this Example, novel DNA sequences capable of functioning
as promoters in the tetracycline resistance gene were produced by:
(1) chemical synthesis of a heterogeneous population of DNA
fragments, 19 basepairs in length, with the nucleotide at each
position of the 19 basepairs being random; (2) insertion of these
DNA fragments into pBR322 plasmids with segments of DNA deleted in
the region of the plasmid known to encode for promoter recognition;
(3) transformation of E. coli bacteria with the recombinant
plasmid; and, (4) selection of transformed host cells by growth in
media containing the antibiotic tetracycline. These steps are
summarized in FIG. 1 and described in detail below.
[0038] Restriction enzymes used in this Example were purchased from
Bethesda Research Laboratories (Gaithersburg, Md.), Boehringer
Mannheim (Indianapolis, Ind.), and New England Biolabs (Beverly,
Mass.), and, except where indicated, use of these enzymes followed
the manufacturers' directions. The enzymes T4 DNA ligase, T4
polynucleotide kinase, large fragment of DNA polymerase I (Klenow
Fragment), and bacterial alkaline phosphatase were purchased from
Bethesda Research Laboratories. Nick-translation reagents
(including DNA polymerase I and DNase I) were purchased from New
England Nuclear (Boston, Mass.) and used according to the
manufacturer's instructions.
[0039] Verification of the promoter recognition sequence in pBR322.
Prior to synthesis of the random population of DNA sequences, the
region of plasmid DNA containing the promoter recognition sequence
for transcription of the tetracycline resistance gene was deleted
using restriction enzymes to verify the importance of this region
for the transcription of that gene.
[0040] The plasmid pBR322 contains a DNA sequence corresponding to
the tetracycline resistance gene, encoding a single, noninducible
43.5 kilodalton polypeptide (Blackman and Boyer, Gene, 26, pp.
197-203 (1983)) that functions at the cell membrane to block
accumulation of the antibiotic tetracycline. McMurry et al.,
P.N.A.S. USA, 77, pp. 2974-3977 (1980). The transcription
initiation site for the gene has been identified by S1-nuclease
protection. Brosius et al., J. Biol. Chem., 257, pp. 9205-9210
(1982). In addition, the position of the promoter recognition site
for the tetracycline resistance gene has been deduced from: (1)
promoter consensus sequence homology in pBR322 (Sutcliffe, Cold
Spring Harbor Symp. Quant. Biol., 43, pp. 77-90 (1979)); (2)
deletion mutations (Rodriquez et al., Nucl. Acids. Res., 6, pp.
3267-3287 (1979)); and (3) electron microscopic mapping (Stuber and
Bujard, P.N.A.S. USA, 78, pp. 167-171 (1981)).
[0041] FIG. 1 shows the tetracycline resistance gene promoter
sequence as described by Sutcliffe, supra. Portions of this
promoter sequence that correspond to the -10 position and -35
promoter recognition site of the consensus sequence are shown in
boxes. Hawley and McClure, Nucl. Acids Res., 11, pp. 2237-2255
(1983). In FIG. 1 the letter "N" indicates unspecified bases.
Restriction enzyme cleavage sites for the endonucleases EcoRI and
Cla I flank the promoter recognition site in the tetracycline
resistance gene. A plasmid designated as pBdEC with a 22 basepair
deletion in the promoter recognition site, extending from the -43
position (in the EcoRI site) to -21 (in the CIa I site) was
constructed by digesting pBR322 DNA with EcoRI and Cla I, purifying
the larger DNA fragment by electrophoresis in low melting
temperature agarose (Bethesda Research Laboratories), filling in
the 5' overhangs with the large fragment of DNA polymerase I in the
presence of all four deoxynucleoside triphosphates, and
recircularizing the blunt-ended fragment with T4 DNA ligase, using
the procedures detailed in Maniatis, supra. The expected deletion
was confirmed by DNA sequence analysis.
[0042] The recircularized plasmids were used to transform E. coli
strain AG1 (Stratagene Cloning Systems, San Diego, Calif.), and E.
coli found to contain the recombinant plasmid were cultured in the
presence of both tetracycline and ampicillin. The manufacturer's
protocol for transformation using these plasmids was followed.
Briefly, transformed host cells were grown in LB for one hour
(approximately two generations) prior to antibiotic selection on
LB-containing agar. Ampicillin concentration in the agar was 50
.mu.g/ml. The transformation efficiency was approximately
5.times.10.sup.3 colonies/.mu.g of ligated DNA. The bacteria were
found to be resistant to a tetracycline concentration of 2 .mu.g/ml
in the absence of a plasmid, to a concentration of 40 .mu.g/ml when
harboring the plasmid pBR322, and to only 4 .mu.g/ml when harboring
pBdEC (the plasmid with the promoter recognition site deleted, as
described above). The DNA sequence in which the promoter
recognition site has been deleted is depicted in FIG. 3.
[0043] Transcription of the tetracycline resistance gene was
identified by northern blot analysis using the procedure as
described by Maniatis et al., supra. Briefly, in this procedure, 5
.mu.g of nucleic acids (DNA and RNA) were purified from the E. coli
AG1 harboring the pBdEC plasmid, using standard procedures, such as
described by Brosius et al., J. Biol. Chem., 257, pp. 9205-9210
(1982), incorporated by reference herein. 114 ng of the extracted
pBR322 DNA was electrophoresed on 1% agarose gel containing 2.2 M
formaldehyde. The gel was then transferred to hybridization
membranes (New England Nuclear) and screened using the 787
basepair, .sup.32P-labeled, nick-translated EcoRV to Nru I
restriction fragment probe from the coding region of the
tetracycline resistance gene in pBR322. Filter hybridization was
performed according to the manufacturer's instructions (New England
Nuclear) and was conducted at 42.degree. C. in 10% dextran sulfate,
1M NaCl, and 1% NaDodSO.sub.4. Filters were washed in 2.times.SSC
and 1% NaDodSO.sub.4 and then 0.1.times.SSC at 25.degree. C.
(1.times.SSC is 0.15M NaCI/15 mM sodium citrate, pH 7.0). Maniatis
et al., supra. The Hind III digest of bacteriophage lambda .lambda.
DNA was used as a size marker. Ethidium bromide staining of the
agarose gel in the absence of formaldehyde was used to ensure that
all lanes contained equal amounts of DNA. The autoradiogram (FIG.
2) was exposed for 8 hours at room temperature on XAR film (Eastman
Kodak, Rochester, N.Y.). A GS 300 Scanning Densitometer (Hoefer
Scientific Instruments, San Francisco, Calif.), which measures the
degree of exposure of the film proportional to the intensity of the
radiation in the autoradiogram, was used to quantify hybridization.
As can be seen from FIG. 2, deletion of the promoter recognition
sequence results in absence of transcription of the tetracycline
resistance gene.
[0044] Synthesis of oligonucleotides. A heterogeneous population of
DNA segments which were random in sequence at each of the 19
basepairs thereof was synthesized by the phosphoramidite method,
using an Applied Biosystems 380A DNA synthesizer (Foster City,
Calif.), and purified by thin layer chromatography as described by
Alvarado-Urbina, et al., in Science, 214, pp. 270-274 (1981),
incorporated by reference herein. The oligonucleotides were
synthesized using approximately equimolar mixtures of
phosphoramidites at each coupling step. The population of
recombinant plasmids produced by insertion of these synthetic DNA
sequences therein, as described below, could yield up to a maximum
of 4.sup.19 (or approximately 3.times.10.sup.11) different
replacement sequences.
[0045] An 8-basepair (bp)-long oligomer, 5'-GGATCGAT-3', was
hybridized to an oligomer 35 bp long,
5'-CCGAATTC(A,C,G,T).sub.19ATCGATCC-3', in a 2:1 molar ratio,
extended with the large fragment of DNA polymerase I, and digested
with an excess of the enzymes EcoRI and Taq I. The 8-bp oligomer
(10.8 .mu.g) and the 35-bp oligomer (24 .mu.g) were annealed in 90
mM NaCl, 15 mM tris-HCl (pH 7.9), and 1 mM MgCl.sub.2 in a total
volume of 120 .mu.l by heating at 65.degree. C. for 5 min and then
at 57.degree. C. for 90 min, followed by immediate chilling on ice
for 15 min. Water and other reagents were added to this reaction to
bring the final volume to 240 .mu.l containing 45 mM NaCl, 3 mM
MgCl.sub.2, 1 mM dithiothreitol, 100 pM of each of the four dNTPs
and 16 units of the large (Klenow) fragment of DNA polymerase 1.
The reaction was incubated for 1 hour at 25.degree. C. and then
terminated by purification on NENSORB columns (New England
Nuclear). The eluate was dried under a vacuum, resuspended in 150
.mu.l containing 50 mM Tris-HCl (pH 8.0), 10 mM MgCl.sub.2, 50 mM
NaCl, and 250 units of the enzyme Taq I. The reaction mixture was
incubated for 21 hours at 37.degree. C. 5 .mu.l containing 50 units
of Taq I were added, and incubation continued for an additional 8
hours at 37.degree. C. 55 .mu.l (250 units) of EcoRI was then
added, and incubation continued for an additional 16 hours at
37.degree. C. Progress of the digestion was monitored by
electrophoresis of the dephosphorylated and .sup.32P-kinased DNA
fragments on a 12% polyacrylamide with 7 M urea sequencing gel, as
described by Perbal, in A Practical Guide to Cloning,
Wiley-Interscience Pub., New York (1984). The restriction fragments
were purified by phenol extraction followed by ethanol
precipitation. Approximately 8 .mu.g of double-stranded DNA derived
from the synthesized oligonucleotides was thereby obtained, a
portion of which was inserted into the plasmid pBR322 as described
below.
[0046] Plasmid construction. Plasmids containing the heterogeneous
population of synthesized and duplexed oligonucleotides,
collectively denoted as plasmid "pRAN4, were produced by digesting
pBR322 with the enzymes EcoRI and Cla 1, removing 5' phosphates
with bacterial alkaline phosphatase, purifying the resulting large
DNA fragment by electrophoresis in low melting temperature agarose
gel, and ligating the appropriate double-stranded DNA restriction
fragment obtained as described above with the vector DNA in a 20:1
DNA insert to vector molar ratio using T4 DNA ligase. Maniatis et
al., supra. The sequences of the random DNA fragments contained in
the plasmids within the pRAN4 population are indicated in FIG. 3
(plasmids pBG8, pBB3, pBB5, pBB9, pBB10, and pBB13).
[0047] Transformation. Competent E. coli cells, strain AG1 (recAl)
prepared as described by Hanahan, J. Mol. Biol, 166, pp. 557-580
(1983), incorporated by reference herein, were purchased from
Stratagene Cloning Systems and used for high efficiency
transformation. All transformed colonies were grown in
Luria-Bertani agar containing 0.1% w/v glucose for 60 minutes
(approximately two generations) prior to antibiotic selection. The
transformants were then placed in LB agar containing 50 .mu.g/ml
ampicillin to identify bacteria carrying recombinant plasmids with
functional random DNA inserts.
[0048] E. coli AG1 was transformed using 410 ng of DNA from the
pRAN4 plasmid population, obtained as described above, at an
efficiency of 10.sup.3 to 10.sup.4 colonies/.mu.g DNA using
ampicillin selection and 10 to 10.sup.2 colonies/.mu.g DNA with
ampicillin and tetracycline selection. Table 1 shows the number of
colonies produced by transformation using pRAN4 (1A) and two other
plasmid populations, pRAN3 and pBT9R (described below).
1TABLE 1 Transformation With Random Plasmid Populations amp
selection amp and tet selection Sequences, no. Sequences, no.
Colonies, Colonies, DNA No. pBR322 Deletions Inserts No. pBR322
Deletions Inserts A. pRAN4 125 2 3 5 28 27 0 1 B. pRAN3 887 0 0 10
23 21 0 2 C. pBT9R 353 114 0 0 4
[0049] Ampicillin selection yielded 125 colonies. To determine the
nature of the DNA insertions present, plasmids from 10 of these
ampicillin resistant colonies were characterized by size
fractionation using electrophoresis on 1% agarose slab gels and DNA
sequence analysis (dideoxy chain termination method). Two plasmids
were found to be identical to plasmid pBR322, and three plasmids
containing deletions bounded by the EcoRI and Cla I sites were
identified (sequences not shown). These plasmids are assumed to be
part of a background of about 50% of the vectors which either
escaped digestion with restriction enzymes or ligation of the
inserted DNA sequence. The remaining five plasmids, pBB3, pBB5,
pBB9, pBB10, and pBB13, were found to contain promoter
substitutions of from 10 to 23 basepairs in length (FIG. 3). Of a
total of 77 bases substituted among these five plasmids, the
average insert length was 15 basepairs long and the composition was
22% adenine, 27% cytosine, 34% guanine and 17% thymine.
[0050] Biological selection using tetracycline. Tetracycline
resistance was used for biological selection for promoter activity
in plasmids containing promoter substitutions of synthetic DNA
sequences. The tetracycline resistance gene or pBR322 previously
has been used as a promoter probe. Widera, et al., Molec. Gen.
Genet., 163, pp. 301-305 (1978); Neve et al., Nature, 277, pp.
324-325 (1979); and West and Rodriquez, Gene, 7, pp. 291-304
(1982). In these experiments, the promoter typically was
inactivated by deletion within the recognition site. Restriction
digests of genomic DNA from prokaryotes and eukaryotes were ligated
into the inactive promoter region as a test of their potential to
restore promoter function. Depending upon the organismal source of
the DNA, insertions with promoter activity were selected at a
frequency of 0.2 to 33% from among all recombinants. In the absence
of DNA sequence data, this high frequency of promoter selection was
explained as either verification of functional promoters (West et
al., Gene, 7, pp. 271-288 (1979)) or as fortuitous restoration of
the deleted portion of the native promoter. Brosius, Gene, 27, pp.
151-160, (1984).
[0051] Tetracycline resistance of the E. Coli containing plasmids
with inserted synthetic DNA sequences was determined by the
efficiency of plating-50% method (EOP.sub.50) described by West et
al. in Gene, 7, pp. 271-288 (1979). Test colonies were inoculated
using a sterile needle on LB agar with 0.1% (w/v) glucose,
containing 0, 1, 2, 4, 6, 8, 10, 16, 20, 30, 40, 50, 60, 70, 80,
90, and 100 .mu.g/ml tetracycline. Inhibitory values were defined
as those which reduced growth, as measured by reduction to one-half
the number of viable colonies.
[0052] Ampicillin and tetracycline selection in combination yielded
28 colonies. To characterize the plasmids from all 28 colonies to
determine if any contained promoter sequences, plasmids were
purified for gel electrophoresis sizing and DNA sequencing by
lysing the host E. coli cells by brief treatment with lysozyme
(Sigma Chemical Co., St. Louis, Mo.), then detergent and sodium
hydroxide. Cell debris was pelleted by centrifugation, and the
plasmid was purified from the cleared supernatant using ethanol
precipitation. Maniatis, et al., supra. Plasmid sizes were then
compared using agarose gel electrophoresis, and about 200
nucleotide basepairs centered at the promoter recognition site were
sequenced. DNA sequencing was conducted using the dideoxy chain
termination method (Sanger et al., P.N.A.S. (USA), 74, pp.
5463-5467 (1977), incorporated by reference herein, directly from
double-stranded pBR322 templates from these rapid preparations.
(Wallace et al., Gene, 16, pp. 21-26 (1981)). 27 plasmids were
found to be identical to pBR322. Again, these are from the
background of unmodified vectors because it is improbable that a
promoter sequence identical to pBR322 would be present within the
small subpopulation of all random sequences selected here. The
other plasmid, pBG8, contained a 38 basepair promoter substitution
(FIG. 3). Although there was sequence length heterogeneity, the
average length of all the pRAN4 substitutions including those not
selected for tetracycline was 19 bases, in agreement with the
length of the synthetic DNA sequences. Therefore, approximately
half of the 125 ampicillin resistant colonies contained plasmids
with promoter substitutions and about 1 out of 63 colonies was also
tetracycline resistant. These results suggest that approximately 2%
of the 3.times.10.sup.11 possible random sequences may duplicate
promoter recognition site activity.
EXAMPLE 2
Production of Novel DNA Sequences Lacking Adenine with Promoter
Activity
[0053] To verify that the synthetic restriction DNA fragments were
responsible for the observed sequence heterogeneity at the promoter
recognition site, and to check for allowable sequence diversity, a
population of plasmids, "pRAN3," was prepared so as to be deficient
in the nucleotide base adenine in the sense strand throughout the
randomly substituted sequences of DNA. Thus, oligonucleotides were
synthesized using an 8-bp oligomer, 5'-GGATCGAT-3', annealed to a
35-bp oligomer, 5'-CCGAATTC(C,G,T).sub.19ATCGATCC-3+ oligomer,
using the procedures described in Example 1 for synthesis of
oligonucleotides. The random plasmid population pRAN3 was produced
as described above for pRAN4 in Example I, by digesting pBR322 with
Eco RI and Cla I, removing 5' phosphates with bacterial alkaline
phosphatase, purifying the larger fragment by electrophoresis, and
ligating these randomly synthesized DNA fragments deficient in
adenine using T4 DNA ligase. Plasmid population pRAN3 contains the
sense-strand promoter recognition site substitutions of random 19
base sequences of cytosine, guanine, and thymine. For this
population, there is a maximum of 3.sup.19 (or approximately
10.sup.9) different, possible replacement sequences. E. coli
bacteria strain AG1 was transformed using 410 ng of pRAN3, as
described in Example 1 for transformation using pRAN4 DNA, at an
efficiency of 10.sup.3 to 10.sup.4 colonies/.mu.g DNA using
ampicillin selection and 10 to 10.sup.2 colonies/.mu.g DNA with
ampicillin and tetracycline selection.
[0054] The results of transformation using pRAN3 plasmids are shown
above in Table 1B. Equal amounts of DNA were used for each
antibiotic selection. Ampicillin selection yielded 887 colonies.
Plasmids from 10 of these ampicillin resistant colonies were
characterized. All 10 of these plasmids, pBA1 through pBA10,
contain replacement insertions of from 15 to 29 nucleotide
basepairs (FIG. 3), implying that greater than 90% of the plasmids
in pRAN3 contain promoter substitutions. Of the total of 203 bases
substituted among these 10 plasmids the average insert length was
20, and the composition was 0% adenine, 32% cytosine, 42% guanine,
and 26% thymine. Because the sequence of the inserted DNA
determines the final sequence composition of the plasmid, these
results indicate that the sequence heterogeneity results from
ligation of the random DNA insert and not from a cellular process
randomly mutating nucleotides within a sequence.
[0055] Ampicillin and tetracycline selection yielded 23 colonies.
Plasmids from all 23 of these ampicillin/tetracycline resistant
colonies were characterized using plasmid purification and
sequencing procedures as described in Example 1. 21 plasmids were
identical to pBR322. The inclusion of adenine in these promoter
sequences indicates that these are from the background of
unmodified vectors and are not present within the small
subpopulation of all random sequences selected here. The other two
plasmids, pBT9 and pBT21, contain promoter substitutions of 19 and
17 nucleotide basepairs, respectively, lacking adenine (FIG. 3). An
additional tetracycline resistant colony containing a plasmid,
pBTR3 (FIG. 3), was detected using replica plating of the colony
growing on the ampicillin media onto ampicillin/tetracycline media.
In this technique, bacteria colonies are removed from one plate and
placed in the same spatial orientation onto a new plate containing
ampicillin and tetracycline (data not shown). Although there was
sequence length heterogeneity, the average length of all pRAN3
substitutions, including those not selected for tetracycline, was
20 bases, close to the 19 basepairs of the synthetic DNA sequences
used for mutagenesis. Therefore, greater than 90% of the 887
ampicillin resistant colonies contained promoter substitutions and
about 2 of these colonies were also tetracycline resistant,
suggesting that approximately 0.2% of the 10.sup.9 possible random
sequences present in this construction may duplicate promoter
recognition site activity. As expected, the absence of adenine
reduced the frequency at which promoter recognition sites were
selected from random sequences.
EXAMPLE 3
Correlation Between Tetracycline Resistance and Transcription of
Tetracycline Resistance DNA
[0056] In order to investigate the correlation of the tetracycline
resistance phenotype with transcription of the tetracycline
resistance gene, E. coli strain DH5.1 cells bearing plasmids
obtained in Examples 1 and 2 and containing promoter recognition
site replacements were tested for resistance to tetracycline
(right-hand column of FIG. 3). The range of tetracycline resistance
conferred by the plasmids selected for ampicillin resistance only
(pBB3, pBB5, pBB9, pBB10, pBB13, and pBA1 through pBA10), was
between 2 and 10 .mu.g/ml. For the ampicillin/tetracycline selected
plasmids (pBG8, pBT9, pBT21, and pBTR3), the range was between 30
and 60 .mu.g/ml, while pBR322 was resistant to 40 .mu.g/ml. Both
pBT9 and pBT21 were found to be resistant to concentrations that
inhibited pBR322, i.e., 50 and 60 .mu.g/ml, respectively.
Tetracycline resistance was measured using the EOP.sub.50 method as
described above in Example 1.
[0057] To show the direct correlation between levels of
tetracycline resistance and the presence of tetracycline resistance
transcript, a northern blot analysis was performed, as described
above, and used to quantify transcription from the tetracycline
resistance gene (FIG. 2). Cellular nucleic acids (both DNA and RNA)
were probed with the 787 basepair EcoR V to Nru I restriction
fragment from the protein coding region for tetracycline resistance
described above in Example 1. The absence of hybridization in
strain DH5.1 lacking plasmid reveals the specificity of this probe.
Hybridization of nucleic acids from strain DH5.1 E. coli harboring
pBR322 detected three bands. The two highest in molecular weight
were plasmid DNA, while the third band (lowest molecular weight)
contained the transcript from the tetracycline resistance gene of
about 1.4 kb maximum length. DH5.1 containing either the
tetracycline sensitive promoter deletion plasmid, pBdEC (Example
1), or the tetracycline sensitive promoter substitution plasmid,
pBA5 (Example 2, pRAN3), revealed an absence of transcription from
the tetracycline resistance gene. DH5.1 harboring the tetracycline
resistance promoter substitutions, pBG8 (from pRAN4 population) and
pBT9, pBT21, and pBTR3 (from pRAN3 population), exhibited a varying
level of tetracycline resistance transcript. The amount of
tetracycline resistance transcript for each plasmid was quantified
using densitometry of the northern blot obtained. Transcript levels
were normalized to plasmid DNA concentrations by taking the
quotient of the values for the 1.4 kb band and the plasmid DNA
bands. Table 2 shows the correlation of phenotype with
transcription.
2TABLE 2 Correlation of Phenotype and Transcription pBT21 pBT9 pBG8
pBR322 pBTR3 pBA5 pBdEC Plasmid tetracycline 1.5 1.25 1.00 1 0.75
0.05 0.05 resistance tet.sup.r transcript 1.27 1.17 1.01 1 0.290 0
0
[0058] All values are expressed relative to those obtained in
pBR322. Thus, there was a direct correlation between the levels of
tetracycline resistance and the tetracycline resistance transcript.
Therefore, the tetracycline resistant phenotype provides a good
estimate of promoter strength in these Examples.
EXAMPLE 4
Demonstration that Tetracycline Resistance is not Produced by Host
Cell Mutation
[0059] To verify that the promoter substitution was in fact the
cause of the tetracycline resistant phenotype, and that a plasmid
mutation rather than a chromosomal mutation was responsible for the
phenotype, secondary transformations using plasmids purified from
the primary ampicillin resistant/tetracycline resistant
transformants were performed. Plasmids pBG8, pBT9, pBT21, and pBTR3
(FIG. 3) were used to transform E. coli strain DH5 (obtained from
Bethesda Research Laboratories) using tetracycline selections with
an efficiency approximately equal to that of pBR322. Therefore,
tetracycline resistance was conferred by mutation of the promoter
region on the plasmid, and not by mutation within the host
bacteria.
Discussion
[0060] The above Examples demonstrate the usefulness of the present
invention for producing novel DNA sequences capable of promoter
activity by biological selection of a population of synthetic DNA
fragments heterogeneous in sequence. Deletion of 19 basepairs at
the -35 promoter region of the tetracycline resistance gene of
pBR322 abolished transcription from the tetracycline resistance
gene of the plasmid. Substitution of these 19 basepairs with random
DNA sequences resulted in a maximum of 4.sup.19 (3.times.10.sup.11)
possible replacement sequences. In a population of about 1000
bacteria that were found to harbor plasmids with these random
substitutions, tetracycline selection identified several functional
-35 promoter sequences. These novel promoters exhibited only
partial homology to the -35 promoter consensus sequence. Further,
two of the sequences (plasmids pBT9 and pBT21, FIG. 3) were found
to promote transcription more strongly than the native promoter.
These promoter sequences differ from all previously identified
promoters and promoter mutations.
[0061] In the tetracycline resistance gene of pBG8, pBT9, and
pBT21, in vivo transcription initiates ten nucleotides downstream
from the pBR322 initiation site, as determined from mapping the 5'
end of the tetracycline resistance mRNA using primer extension as
described by McKnight et al., Cell, 25, pp. 385-398 (1981).
Briefly, an oligonucleotide primer was hybridized to a sequence
within the tetracycline resistance gene. Synthesis of a
complementary strand by reverse transcription produced a DNA
sequence whose length is indicative of the distance between the 5'
mRNA end and the location of the known primer.
[0062] While all four of the promoter recognition regions obtained
in the above Examples retain homology with the consensus sequence,
in three of those sequences, pBG8, pBT9, and pBT21, the consensus
alignment is shifted ten nucleotides downstream (FIG. 3). In these
three promoters, in vivo transcription initiation also shifts ten
nucleotides downstream. The RNA polymerase therefore recognizes a
new Pribnow box from within the original pBR322 sequence. A
candidate Pribnow box, ten nucleotides downstream from the original
Pribnow box, is TGCGGTAGTTT, wherein agreement with the consensus
sequence has been underlined. Supporting evidence comes from a
mutation in the lac promoter in which a base substitution at
position +1 (downstream) activates a latent Pribnow box to initiate
transcription at position +13. Maquat et al., J. Mol. Biol., 139,
pp. 551-556 (1980).
[0063] The functional tetracycline resistance promoter in pBTR3 has
conserved the consensus spacing of 17 nucleotides between the
position -35 and -10 promoter elements. However, the nonfunctional
tetracycline resistance promoter in pBA7 retains substantial
homology with the consensus sequence, but not the spacing. These
promoter mutations demonstrate the significance of the spacing
between the two promoter elements.
[0064] From among the more than 150 known promoters and promoter
mutations (McClure, Ann. Rev. Biochem., 54, pp. 171-204 (1985)),
the only "up" mutation that decreases homology to the consensus
sequence is found in -35 region of the arg promoter (Horwitz et
al., J. Bacteriol., 142, pp. 659-667 (1980)), and there are no
"down" mutations that increase homology with the consensus
sequence. Among the sequences described herein, pBTR3 contains
decreased homology with the consensus sequence, relative to pBR322,
and is a down mutation. However, pBT9 and pBT21 contain
tetracycline resistance promoters with decreased consensus homology
at both promoter elements, yet are both up mutations. While these
results highlight the importance of the promoter consensus
sequence, they also surprisingly indicate that deviations from the
consensus need not necessarily decrease promoter activity.
EXAMPLE 5
Demonstration that Synthetic DNA Sequences Function Within the
Plasmid to Produce Tetracycline Resistance
[0065] In order to unambiguously establish that the promoter
replacements are the elements of the plasmid responsible for
tetracycline resistance, one of the plasmids (pBT9) was
reconstructed. Oligonucleotides of known sequence were used to
duplicate the promoter substitutions (FIG. 3) found in pBT9. Two
oligonucleotides, each identical to one of the two DNA strands of
the promoter recognition region in this plasmid were chemically
synthesized.
[0066] Construction of pBT9R. A 26-bp oligomer,
5'-AATTCTTGGGCGCGCGTCGGCTT- GAT-3' (17 .mu.g), was annealed to a
24-bp oligomer, 5'-CGATCAAGCCGACGCGCGCCCA-AG-3' (16 .mu.g), in a
1:1 molar ratio in a reaction mixture containing 90 mM NaCl, 15 mM
tris-HCl (pH 7.9), and 1 mM MgCl.sub.2 to form a total volume of
200 .mu.l. The mixture was heated at 65.degree. C. for 5 min and
then at 57.degree. C. for 90 min, followed by immediate chilling on
ice for 15 min Incubation with T4 polynucleotide kinase in the
presence to ATP was used to add 5' phosphoryl termini. Maniatis et
al., supra. The resulting product contained EcoRI and Cla I
cohesive ends. The synthetic 26-oligomer was of the same sequence
as pBT9 in the nontemplate strand extending from the EcoRI
restriction site at position -47 to the Cla I restriction site at
position -21. The complementary synthetic 24-oligomer had a
sequence equivalent to that of the template strand of pBT9
(position -43 to position -18). The annealed synthetic
oligonucleotides were then ligated into the EcoRI and Cla
I-digested pBR322. The resulting construct was designated plasmid
pBT9R.
[0067] E. coli strain DH5 was transformed using 50 ng of pBT9R DNA
to produce 353 ampicillin resistant and 114 ampicillin
resistant/tetracycline resistant colonies, at an efficiency of
7.times.10.sup.3 colonies/.mu.g DNA using ampicillin selection, and
2.times.10.sup.3 colonies/.mu.g using ampicillin and tetracycline
selection (Table 1C). Plasmids from 4 of the ampicillin
resistance/tetracycline resistance colonies were characterized, as
described above, by plasmid purification and DNA sequencing.
Plasmid sizes were compared using agarose gel electrophoresis, and
approximately 200 basepairs centered at about position -35 were
sequenced. The results are shown in FIG. 3. Plasmids from all four
colonies contained insertions in the expected region. Three
colonies contained a plasmid, pBT9R, identical to that of pBT9,
while the other colony contained a plasmid that included the
sequence present in pBT9 but with an extra insertion of three
basepairs upstream. In the absence of plasmid, DH5 was found to be
resistant to a tetracycline concentration of 2 .mu.g/ml. When
harboring pBT9R, the reconstruction of pBT9, DHS was resistant to a
tetracycline concentration of 50 .mu.g/ml, the same level of
resistance which the original pBT9 conferred on DH5.1. Therefore,
tetracycline resistance was conferred by the promoter substitutions
and not by a mutation elsewhere on the plasmid.
Discussion
[0068] The results of the above Examples are summarized in FIG. 3.
The consensus promoter sequence as previously identified by Hawley
and McClure, Nucl. Acids Res., 11, pp. 2237-2255 (1983), is shown
on the top line of FIG. 3. The bases found to be most strongly
conserved in the consensus are shown in upper case. The sequence of
pBR322 is depicted next, below the consensus sequence. Following
pBR322 are the substitutions for the promoter sequence obtained by
insertion of the synthetic DNA sequences as described in preceding
Examples. Spaces have been inserted before and after the pBR322
promoter sequence and the promoter substitutions to maximize
alignment with the consensus sequence and facilitate visual
comparison. Portions of sequences exhibiting homology with the
consensus sequence are enclosed in boxes. Dashes indicate positions
in the sequence identical to that in pBR322. Bases within the
dashes which match the pBR322 indicate positions within pBR322,
outside of the substitution obtained using the synthetic DNA
sequences, that, together with the substitution, provide homology
with the promoter consensus sequence (-35). Two plasmids, pBTR3 and
pBA8, possess downstream insertions, a possible artifact from
plasmid construction, indicated as subscripts in the dashes (e.g.,
TCC in pBTR3). Three plasmids, pBA7, pBT9, and pBT21, have two
sites of potential alignment with the consensus sequence; although
not aligned, bases in the alternate site are underlined in the
FIGURE. Tetracycline resistance was determined as described
above.
EXAMPLE 6
Selection of Novel Leader Sequences
[0069] Plasmid construction. A plasmid designated pBdBLA is
constructed containing DNA encoding the gene for .beta.-lactamase,
lacking the coding region for the leader sequence for this protein,
and containing a restriction endonuclease recognition site at the
immediate 5' terminus of the coding region, so that synthetic,
random DNA sequences may be conveniently ligated in place.
[0070] The parent plasmid pBdBLA, into which the random DNA
sequences will be inserted, is constructed using techniques of M13
site directed mutagenesis similar to that described by D. M.
Glover, supra. The modification of the pBR322 .beta.-lactamase gene
is more easily accomplished if the gene is temporarily transferred
to a bacteriophage M13 vector. The M13 mp family of bacteriophage
vectors facilitates site-directed mutagenesis because they can be
conveniently isolated in single-stranded form. The EcoRI to Pst I
restriction fragment of pBR322 is cloned into M13 mp10. The 5'
portion of the .beta.-lactamase gene is contained on the EcoRI to
Pst I restriction fragment of pBR322. M13 mp10 is particularly
useful because it contains unique EcoRI and Pst I restriction
sites. Messing, J., Methods in Enzymology, 101, p. 20 (1983).
[0071] Restriction endonucleases and enzymes of nucleic acid
metabolism are purchased from commercial sources and used according
to the manufacturers' instructions. In addition to the well-known
protocols for M13 site-directed mutagenesis, standard techniques of
molecular cloning are used. The plasmid pBR322 is digested with
EcoRI and Pst I, and this restriction fragment is purified by
electrophoresis in low melting temperature agarose. The restriction
fragment is ligated into similarly digested M13mp10 vector.
[0072] Two mutagenic steps are required. The first produces a
deletion of the existing leader sequence. The second produces an
insertion of a unique restriction site so that the random DNA
sequences may be ligated in place.
[0073] In the first step, the distal 66 bases of the 69 base DNA
sequence coding for the leader polypeptide are deleted. The first
three bases, functioning as an ATG initiation codon, are preserved.
The mutagenic 20-mer oligonucleotide, 5'-TTTCTGGGTGCATACTCTTC-3',
is hybridized to the .beta.-lactamase gene in the single-stranded
M13mp10 recombinant plasmid, so as to abridge (i.e., remove or
"loop-out.infin.) the leader sequence. The mutagenic 10-mer primer
consists of two 10-base-long "arms" which flank either side of the
leader sequence. In vitro copying using the large (Klenow) fragment
of DNA polymerase I produces a partially duplex plasmid in which
one strand contains a leader sequence deletion. Complete
duplication of the mutant DNA strand is accomplished in vivo. The
resulting deletion is verified using standard DNA sequence
analysis, as described above in Example 1.
[0074] In the second step, a mutagenic primer that is a derivative
of the first primer is used to insert a unique Bgl II restriction
site at the 5' terminus of the leaderless, .beta.-lactamase gene.
pBR322 lacks a Bgl II site. The mutagenic 26-mer,
5'TTTCTGGGTGAGACCTCATACTCTTC-3', is hybridized to the leaderless
.beta.-lactamase gene in the single-stranded M13mp10 recombinant
plasmid, so as to insert a six-base Bgl II restriction site
(5'-AGATCT-3') immediately 3' to the remaining ATG initiation
codon. As above, both in vitro and then in vivo polymerization are
used to complete the synthesis of the mutant DNA strand. The
resulting insertion is verified by DNA sequence analysis, as
above.
[0075] Finally, the mutagenized .beta.-lactamase gene fragment is
recovered from M13mp10 and reinserted into pBR322 to complete the
construction of pBdBLA. The m13mp10 recombinant plasmid is digested
with EcoRI and Pst I, and the restriction fragment is purified by
agarose gel electrophoresis. The restriction fragment is then
ligated into similarly digested pBR322. The resulting product,
containing a leaderless .beta.-lactamase gene (with a unique
restriction enzyme adjacent to the ATG initiation codon), is
verified using DNA sequence analysis.
[0076] Production of random DNA sequences. Random DNA fragments
containing Bgl II compatible ends may be ligated into pBdBLA to
select for leader function. To produce these random DNA fragments a
74-mer oligonucleotide, 5-GGGGAGATCT(A,C,G,T).sub.54AGA-TCTGGGG-3',
is hybridized to a complementary 10-mer oligonucleotide,
5'-CC-CCAGATCT-3'. In a manner equivalent to that set forth above,
in Examples 1 and 2, the partial duplex is copied with the large
Klenow fragment of DNA polymerase I and digested using Bgl II. The
restriction fragments are ligated into pBdBLA that has been cleaved
with Bgl II and treated with bacterial alkaline phosphatase to
produce a population of plasmids containing heterogeneous random
DNA sequences inserted in place of the deleted native leader
sequence.
[0077] The random stretch of 54 bases, coding for 18 amino acid
residues, any of which may be one of the 20 amino acids used in
protein synthesis, will allow for a maximum of 20.sup.18 (about
3.times.10.sup.23) different possible sequences. (Four more amino
acid residues, an argenine and a serine residue at both sides of
these 18 residues, will be coded for by the Bgl II recognition
site). Out of every 64 codons, 61/64 will not be termination
codons; thus, there will be a total of
(61/64).sup.18.times.20.sup.18 (approximately 10.sup.23) random
sequences that will not contain termination codons and will allow
for an open reading frame. The fraction of random sequences
containing open reading frames, and the residue composition (i.e.,
relative hydrophobicity or hydrophilicity) may be altered by
biasing the DNA base composition in the random sequence. For
example, because all termination codons contain adenine, a
deficiency of adenine in the random stretch will greatly reduce the
frequency of termination codons. Because the random insertions are
of length equal to the native sequence, frameshifts are not
expected.
[0078] To select those DNA sequences with secretory activity, the
random plasmid population is used to transform E. coli using
selection with ampicillin and tetracycline as described above in
Example 1. Tetracycline will select for bacteria containing
plasmids bearing inserts (as the pBR322 tetracycline resistance
gene is left intact in pBdBLA), and ampicillin will select for
functional leader sequences. The random plasmid population
transforms E. coli strain DH5 at high efficiency (Hanahan, supra.).
The tetracycline concentration in the media is 12.5 .mu.g/ml, and
ampicillin concentration is 50 .mu.g/ml. Transformants are
amplified by growth in LB at 37.degree. C. for 1 hour
(approximately two generations) prior to antibiotic selection on LB
agar. Because pBdBLA contains a deletion of the leader sequence,
pBdBLA will be ampicillin sensitive. Therefore, ampicillin
resistant transformants will contain functional leader sequences.
These novel, functional leader sequences may be further
characterized by DNA sequence analysis. All resulting sequences
will be flanked by Bgl II restriction sites, facilitating their
transfer to other genes and/or plasmids, for further analysis or
subsequent use.
[0079] The above procedure allows for the direct selection, rather
than the tedious screening, of functional leader sequences. Leader
sequences are thus selected from a population of synthetic random
DNA, rather than from organismal DNA of known or putative secretory
activity. Because novel leader sequences may be identified, useful
and unique properties may be selected. For example, this technique
may be used to create leader sequences capable of functioning in a
wide variety of different organisms, or leader sequences that
retain activity in inhospitable physical environments.
EXAMPLE 7
Selection of Novel Proteins
[0080] Plasmid Vector. The plasmid ptac-85 has been engineered for
the expression of gene fragments lacking a promoter, a
ribosome-binding site, and an initiation codon. Marsh, P., Nucleic
Acids Research, 14, p. 3603 (1986), incorporated by reference
herein. Another useful plasmid is pKK 233-2, available from
Pharmacia Fine Chemicals (Piscataway, N.J.). Insertion of DNA at
the BamH I site of this plasmid will produce an open reading frame,
from which the random DNA fragments may be translated into random
proteins. Recombinant ptac-85, containing inserted random DNA
produced as described below, is used to transform E. coli strain
DH5 at high efficiency. Hanahan, supra. Because ptac-85 contains an
ampicillin resistance gene, growth in ampicillin will select for
transformants.
[0081] Production of random DNA sequences. Long, random DNA
sequences are produced using the enzyme terminal deoxynucleotidyl
transferase (hereafter "TdT") or by chemical synthesis. In either
case, standard techniques of molecular cloning are employed
throughout. Maniatis et al., supra. All reagents and enzymes,
including TdT, are available from Pharmacia, as well as from other
suppliers.
[0082] TdT will catalyze the random addition of deoxynucleotide
triphosphates to the 3' termini of DNA, and has previously been
used to produce random protein coding DNA sequences of 400
nucleotides in length. Damiani, G., et al., Nucleic Acids Research,
10, pp. 6401-6410 (1982), incorporated by reference herein.
Briefly, this protocol consists of the following: (i) randomly
tailing with TdT a short, single-stranded random oligomer to
produce a single-stranded DNA of about 900 nucleotides in length;
(ii) making this single-stranded DNA double stranded by hybridizing
it to the same short, single-stranded random oligomer and copying
it with the large fragment of DNA polymerase I; (iii) blunt-end
digesting the resulting double-stranded DNA using the
single-strand-specific enzyme S1 nuclease; and (iv) ligating BamH I
linkers onto the final, random, double-stranded DNA in preparation
for cloning into the parent vector. Single-stranded DNA of 5
nucleotides in length (p(dN).sub.6), from a limit digest of
calf-thymus DNA (Pharmacia, Piscataway, N.J.), is randomly tailed
by TdT. A typical 100 .mu.l reaction containing 50 ng p(dN).sub.6,
10 units TdT, 100 mM potassium cacodylate (pH 7.0), 1 mM
CoCl.sub.2, 0.2 mM dithiothreitol, and 0.25 mM of each of the
deoxynucleotide triphosphates (dNTPs) is incubated for 1 hour at
37.degree. C. This reaction produces approximately 9 .mu.g of
random DNA sequences of a mean length of approximately 900
nucleotides. The resulting product is purified by phenol/chloroform
extraction and ethanol precipitation. The length of the resulting
product may be verified using electrophoresis on a 1.5% agarose
gel, or, if a label such as .alpha.-.sup.32 phosphorus is
incorporated into the dNTPs, both the length and base composition
of the resulting product may be determined by precipitation in 10%
trichloroacetic acid. Maniatis et al., supra.
[0083] The base composition of the final product may be biased by
altering the dNTP concentrations in the initial reaction. For
example, to reduce the frequency of termination codons appearing in
the random DNA sequences, the concentration of dATP may be reduced,
because all three of the termination codons contain adenine. To
make the DNA from the above reaction double-stranded, it is
hybridized with a five-fold molar excess of p(dN).sub.6 in 90 mM
NaCl, 15 mM tris-HCl (pH 7.9), and 1 mM MgCl.sub.2 in a total
volume of 120 .mu.l by heating at 65.degree. C. for 5 min and then
57.degree. C. for 90 min, followed by immediate chilling on ice for
15 min The concentration of this mixture is then adjusted to 2 mM
MgCl.sub.2, 1 mM dithiothreitol, 100 .mu.M of each of the dNTPs,
and 25 units of the large (Klenow) fragment of DNA polymerase I in
a final volume of 240 .mu.l and incubated at 37.degree. C. for 60
min The approximately 18 .mu.g of double-stranded DNA produced from
the above reaction is purified by phenol/chloroform extraction and
ethanol precipitation. Next, the DNA is digested with the
single-strand-specific S1 nuclease to ensure that it is blunt
ended. The above DNA is reacted with 100 units of S1 nuclease in
200 .mu.l containing 30 mM sodium acetate (pH 4.6), 50 mM NaCl, 1
mM ZnCl.sub.2, and 5% glycerol and incubated at 37.degree. C. for
30 min The resulting blunt-ended, double-stranded DNA
(approximately 15 .mu.g) is purified by phenol/chloroform
extraction and ethanol precipitation. To prepare the blunt-ended,
double-stranded random DNA for insertion into the cloning vector,
this purified DNA is ligated to BamH I linkers (Pharmacia,
Piscataway, N.J.) and digested with BamH I, both done using
standard techniques. Maniatis et al., supra
[0084] The random DNA is next ligated into the parent vector, using
standard techniques.
[0085] Growth Selection. The novel catalytic activity is identified
from the above transformants by growth in a selective medium. To
isolate DNA sequences encoding a novel protein capable-of
conferring tetracycline resistance, the above transformants are
grown on LB agar containing 12.5 .mu.g/ml tetracycline.
[0086] One construction of a random plasmid population may suffice
to select for a plurality of novel protein activities. For example,
to create each new catalytic activity, only the final selection
phase need be altered. Additionally, since each construction of a
random plasmid population will contain a small subset of all
possible protein sequences, for any given catalytic activity, each
random plasmid population will yield a different protein
sequence.
[0087] An alternative application of the above procedure is its use
to modify only the active site of a known protein. In an entire
protein DNA sequence, only a few amino acid residues (i.e., those
encoding the "active site") are actually involved in enzymatic
catalysis. By mutagenizing DNA encoding a gene so as to create a
heterogeneous population of modified genes, each different and
random in sequence at the active site, DNA sequences encoding new
or modified catalytic activities may be selected.
[0088] Although targeted mutagenesis has been used by others to
define the location of functional sequences within prokaryotic and
eukaryotic DNA, the base changes from the wild-type sequence were
limited in number, presumably because of the premise that most
functional sequences resemble those already known. In these
methods, new, functional DNA sequences were not produced. In
contrast, the method of the present invention applies biological
selection to an exceptionally large and diverse population of
random DNA sequences, and enables rapid screening of large amounts
of synthetic DNA to identify novel functional DNA sequences. The
present method may be used to select novel sequences from large
populations of possible DNA sequences, rapidly and with relatively
little effort, since transformation and selection may be
accomplished without requiring prior characterization of the
synthetic DNA sequences inserted. Because this process allows for
direct selection from large, random populations of DNA sequences,
prior knowledge of structure-function relationships with respect to
specific regions of DNA is not required to generate novel,
functional sequences. However, the process of this invention may be
used to provide information as to structure and function
relationships of specific regions of DNA encoding biological
activity. This invention may be used for the selection of DNA
sequences encoding peptide hormones, and related effector molecules
such as growth factors, leader sequences for secreted peptides,
catalytic domains, genetic markers, and even entire enzymes and
other proteins in prokaryotes or eukaryotes. Genetic regulatory
elements, including promoters, enhancers, origins of replication,
transcription terminators, centromeres, and telomeres may also be
produced or evaluated by the method of this invention.
EXAMPLE 8
Mutants Generated by the Insertion of Random Oligonucleotides into
the Active Site of the .beta.-lactamase Gene
[0089] We have remodeled the gene coding for .beta.-lactamase by
replacing DNA at the active site with random nucleotide sequences.
The oligonucleotide replacement (Phe.sup.66 XXX Ser.sup.70 XX
Lys.sup.73) preserves the codon for the active serine-70 but also
contains 15 base pairs of chemically synthesized random sequences
that code for 2.5.times.10.sup.6 amino acid substitutions (x). From
a population of E. coli infected with plasmids containing these
random inserts, we have selected seven new active site mutants that
render E. coli resistant to carbenicillin and a series of related
analogs. Each of the new mutants contains multiple nucleotide
substitutions that code for different amino acids surrounding
serine-70. Each of the mutants exhibits a temperature sensitive
.beta.-lactamase activity. This technique thus permits the
construction of alternative active sites in enzymes based on
biological selection for functional variants.
[0090] For studies on the active sites of enzymes we chose to
insert random nucleotide sequences into the gene for RTEM-1
.beta.-lactamase (EC 3.5.2.6) that is present in the plasmid pBR322
(Mathew & Hedges, 1976; see the citations listed below).
Bacterial .beta.-lactamases hydrolyze the .beta.-lactam ring of
penicillin or cephalosporin transforming them into reactive
metabolites. The mechanism of catalysis by the class A enzymes
involve a transient acylation of the serine residue at position 70
(Ambler, 1980). The nucleotide sequence and three dimensional
structure of several class A .beta.-lactamases have been determined
(Herzberg & Moult, 1987) and indicate a high level of
conservation of amino acids surrounding the active Ser-70. Schultz
and Richards (1986) used site saturation mutagenesis to show that
even though Thr-71 is conserved, it can be replaced by 14 of the 20
amino acids substituted. Thus, despite the evolutionary
conservation of one amino acid within the active site there could
be a high degree of tolerance for substitutions. .beta.-lactams and
cephalosporins are among the most frequently prescribed class of
pharmaceuticals worldwide, and the rapid evolution of
.beta.-lactamases in pathogenic bacteria continues to defeat the
best efforts of chemists to create new resistant analogs (Bush,
1988).
[0091] We have replaced a portion of the active site of
.beta.-lactamase in the plasmid pBR322 with an oligonucleotide that
retains the codon for the active Ser-70 but also contains two
flanking sequences of six and nine random nucleotides. In these
experiments we have screened 2.times.10.sup.5
tetracycline-resistant (tet.sup.r) colonies of E. coli infected
with plasmids containing random inserts and obtained seven new
carbenicillin resistant mutants. DNA sequence analyses of the
mutants indicate that multiple amino acid substitutions within the
active site can be tolerated and are compatible with enzymatic
activity. Furthermore, nucleotide substitutions involving
evolutionarily conserved amino acids alter substrate specificity
and temperature stability.
Experimental Procedures
[0092] Materials. Oligonucleotides were synthesized using
phosphoramidite chemistry by Operon Technologies (San Pablo,
Calif.). The following two oligonucleotides, each 47 nucleotides in
length, were used as templates for the construction of the random
inserts:
3 i) 5'-CGCCCCGAGGAACGTNNNNNNNNNNNNNNNNNNNNNNNAGTACTGCT-3'; ii)
5'-CGCCCCGAGGAACGTTTTNNNNNNNNNAGCNNNNNNAAAGTACTGGT-3.
[0093] The stretches of random nucleotides (designated by the Ns)
within these inserts were synthesized using equimolar mixtures of
nucleoside phosphoramidite derivatives. Restriction endonucleases
were obtained commercially and were used according to the
suppliers' instructions. Standard molecular cloning methods were
employed (Maniatis, et al., 1982).
[0094] Plasmid construction. The vector for the insertion of random
sequences, pBDL, is a modification of pBR322 containing within the
ampicillin gene two unique restriction sites located on either side
of the nucleotides coding for Ser-70. pBDL was assembled by
ligating together two modified segments of pBR322 (FIG. 4). The
first segment was obtained from the plasmid pBR322-R, a generous
gift of Dr. J. H. Richards (California Institute of Technology,
Pasadena, Calif.). It is a modification of pBR322 that contains an
Ava I and a Sca I site centered at positions 3972 and 3937,
respectively, as well as an additional AvaI site at 1425 (Schultz
& Richards, 1986). Digestion with Pst I and Sph I yielded a
fragment of 1315 bp that contained a portion of the ampicillin gene
and lacked the second AvaI site.
[0095] The second segment was obtained by the following steps:
digestion of wild-type pBR322 with Ava I and Pvu II, purification
of the large fragment by electrophoresis and electroelution,
filling in the Ava I termini with E. coli Pol I, and blunt end
ligation with T4 DNA ligase. The resultant 3725 bp plasmid was also
digested with Sph I and Pst I, and the 2410 bp fragment was
purified by electrophoresis and ligated onto the first segment.
[0096] Synthesis of Random Oligonucleotides. The double-stranded
oligonucleotide used in the construction of the nonproducer strain,
pBNP, was synthesized by hybridizing 200 ng of 9-mer primer,
5'-AGCAGTACT-3', to 1 .mu.g of the single-stranded oligonucleotide
template, 5'-CGCCCCGAGGAACGT (N)23 AGTACTGCT-3', in 20 mM Tris-HCl
(pH 7.5), 10 mM MgCl.sub.2, 50 mM NaCl, and 1 mM dithiothreitol at
65.degree. C. for 10 min This template-primer was extended with the
large fragment of E. coli Pol I, digested with Ava I and Sca I and
purified by polyacylamide gel electrophoresis. The double-stranded
oligonucleotide for the construction of the plasmid used in
selecting new mutants was synthesized by a similar protocol: 200 ng
of 9-mer primer 5'-AGCAGTACT-3' was hybridized to 1 .mu.g of the
template oligonucleotide:
[0097] 5'-CGCCCCGAGGAACGTTTT (N).sub.9 AGC(N).sub.6
AAAGTACTGCT-3'.
[0098] The template-primer was extended with E. coli Pol I,
digested with Ava I and Sca I, and used as a replacement for the
insert in the nonproducer strain.
[0099] Other Methods. The preparation of competent DH5.alpha. and
DH5 E. coli and subsequent transformation with plasmid DNA were
carried out according to the protocol of Hanahan (1983).
Transformants were grown in "SOC" medium for 1 hr prior to
antibiotic selection. We scored for carbenicillin resistance by
incubating the transfected E. coli in petri dishes in agar
containing 12.5 .mu.g/ml tetracycline and 50 .mu.g/ml carbenicillin
at 30.degree. C. for 48 hrs. Plasmid DNA was purified by the
alkaline lysis method (Maniatis, et al., 1982), and sequencing of
both strands was carried out on double-stranded DNA purified by
isopicnic density centrifugation using dideoxy chain termination
(Sanger, et al., 1977). .beta.-lactamase activity was scored using
the chromogenic cephalosporin: pyridinium-2-azo-p-dimethvl aniline
chromophore (PADAC) (Kobayashi, et al., 1988). An overnight culture
of each test mutant was diluted 1,000-fold with the fresh broth,
and a 5 .mu.l inoculum (10.sup.-4 CFU per spot) of each sample was
applied onto agar plates containing 50 .mu.M PADAC and 12.5
.mu.g/ml tetracycline. After 18-20 hr incubation at 30.degree. C.
the diameter of the PADAC hydrolysis zone formed around the colony
was determined. The highest antibiotic concentration permissible
for growth of E. coli was determined using antibiotic concentration
gradients generated in L-agar plates (Schultz, 1987).
Results
[0100] In order to substitute random DNA sequences for designated
nucleotides at the active site of the .beta.-lactamase gene we
first constructed a derivative of plasmid pBR322 that contains two
unique restriction sites flanking the targeted sequence (see
Experimental Procedures). The new DNA vector contained both the
tetracycline and ampicillin resistance genes. Within the ampicillin
resistance gene are Ava I and Sca I sites centered at positions
3329 and 3294, respectively.
[0101] Since it is likely that only a small fraction of random
nucleotide sequences at the active site of .beta.-lactamase code
for viable amino acid substitutions, and since it is difficult to
completely cleave restriction sites when present at the ends of
double-stranded DNA (Horwitz & Loeb, 1986), we designed a two
step strategy to minimize contamination with wild-type sequences.
We first constructed a nonproducer plasmid, pBNP, that contains an
inactive nucleotide replacement, obtained DNA from isolated clones,
and then exchanged the inactive sequence with a random nucleotide
sequence to be used for mutant selection.
[0102] The nonproducer was obtained by digesting the modified
pBR322 (FIG. 4) with Ava I and Sca I and inserting a
double-stranded 47 oligomer that contains a 23 base random
nucleotide sequence (FIG. 5A). Plasmid infected E. coli were
selected based on resistance to tetracycline and then screened for
sensitivity to low concentrations of carbenicillin (10 .mu.g/ml). A
tet.sup.r clone was selected that was sensitive to all of the
analogs tested and exhibited no detectable .beta.-lactamase
activity (FIG. 6). DNA sequence analysis demonstrated that this
clone contains a 23 base pair insert between Arg-66 and Val-74 (the
Ava I and Sca I sites) and codes for an amino acid sequence having
no homology with the wild type sequence and also containing a
single base frameshift at the carboxy terminus of the insert.
[0103] For the construction of active site mutants, DNA from the
nonproducer strain was digested with the same two restriction
enzymes and purified by agarose gel electrophoresis. Into this DNA
was ligated an oligonucleotide containing an AGC codon for serine
flanked by stretches of nine and six random nucleotides (FIG. 5B).
Nonselective growth in the presence of tetracycline in four
separate experiments yielded a total of approximately
2.times.10.sup.5 colonies. Seven of the tetracycline resistant
colonies were also resistant to carbenicillin (50 .mu.g/ml) (FIG.
6, mutants 1-7). Each of the carbenicillin resistant clones
contained the AGC codon at amino acid position 70. The distribution
of nucleotides within the random positions in the mutants is: 39%
C, 28% T, 23% A, and 10% G. The less than equal representation of G
in the coding strand of the insert could be the result of a bias in
the incorporation of nucleotides during chemical synthesis or could
be indicative of the repertoire of substitutions that yield active
molecules. Considering all seven mutants, 53% of the nucleotides in
the random positions do not correspond to those in the parent
strain. Of the 35 codons capable of being substituted, 32 contained
nucleotide substitutions; 10 of these were silent, and 22 resulted
in amino acid changes. Of the five substituted amino acids, the
proline at position 67 is the most conserved; however, it is still
lacking in one of the new sequences.
[0104] The resistance of E. coli infected with each of the mutant
DNAs was quantified by observing the extent of bacterial growth on
agar plates containing concentration gradients of carbenicillin,
ampicillin or benzylpenicillin. At 30.degree. C., the control
strain, pBDL, was resistant to each of the antibiotics at >500
.mu.g/ml, while the nonproducer strain, pBNP failed to grow at the
lowest concentration in the gradient. The extent of resistance was
confirmed by using agar plates containing defined concentrations of
each of the antibiotics. At 30.degree. C., mutants 2, 3, 4, and 6
rendered E. coli resistant to the highest concentration of
antibiotic tested. However, at the elevated temperatures, all of
the mutants were more sensitive to the antibiotics than was the
control, pBDL. Mutant #7 was the most sensitive to each of the
antibiotics. All the other mutants are more resistant towards
carbenicillin than ampicillin or benzylpenicillin, particularly at
higher temperatures. A chromogenic cephalosporin, PADAC, was used
to measure .beta.-lactamase activity of each of the mutant-infected
E. coli. In general, the resistance of the mutants to carbenicillin
and the other .beta.-lactam antibiotics parallels the production by
.beta.-lactamase as measured by the hydrolysis of PADAC. However,
differences in the relative resistance of the mutants to the
different analogs suggest that some of the .beta.-lactamase mutants
exhibit altered substrate specificity.
[0105] To unambiguously establish that the replacement at the
active site was responsible for the carbenicillin resistance in
plasmid-infected E. coli, we reassembled one of the new mutants. We
chemically synthesized a double-stranded oligonucleotide identical
to the sequence of nucleotides in mutant #1 (FIG. 6). This
oligonucleotide was used to replace the insert in the nonproducer
strain. A comparison of the drug resistance of E. coli infected
with mutant #1 containing the biologically selected random sequence
and that bearing the chemically synthesized insert (Mutant 1R) is
included in the following Table 3. The pattern of resistance is
identical. Thus, antibiotic resistance is conferred by the
substitution at the active site and not by some other mutation
within the plasmid or within the E. coli chromosome.
4TABLE 3 Maximum level of resistance and PADAC hydrolysis zone of
strains with mutations at .beta.-lactamase Diameter of Maximal
antibiotic concentration (mg liter) PADAC hydro- permitting
bacterial growth lysis zone Carbenicillin Ampicillin Benz.
Penicillin (mm) Strain/Mutant 30.degree. 37.degree. 42.degree.
30.degree. 37.degree. 42.degree. 30.degree. 37.degree. 42.degree.
30.degree. Wild Type >500 >500 >500 >500 >500
>500 >500 >500 >500 20 Non Producer NG NG NG NG NG NG
NG NG NG <4 Mutant #1 >500 75 NG >500 100 NG 250 NG NG
<4 Mutant #1R >500 75 NG >500 100 NG 250 NG NG <4
Mutant #2 >500 >500 200 >500 >500 80 >500 >500 50
14 Mutant #3 >500 >500 70 >500 160 NG >500 NG NG 10
Mutant #4 >500 >500 220 >500 330 75 >500 40 NG 6 Mutant
#5 320 83 NG 400 55 NG 250 NG NG <4 Mutant #6 >500 >500 75
>500 420 NG >500 170 NG 6 Mutant #7 110 NG NG 310 100 NG 190
NG NG <4
[0106] Antibiotic resistance was determined by concentration
gradients, as described in Experimental Procedures. In Table 3,
NG=no growth observed. PADAC hydrolysis of less than 4 mm in
diameter could not be visualized due to growth of bacteria. One of
the mutant sequences was duplicated into a second plasmid to rule
out mutations outside the site of random sequence insertion. The
insert of mutant #1 was reconstructed in plasmid pBNP by ligating
into it a double stranded oligonucleotide: 47-mer
5'-CGCCCCGAGGAACGTTTTCCCGTCATGAGCATCATCAAAGTACTGCT-3', and its
complement. The double stranded oligo was constructed as described
in Experimental Procedures, and then digested with Ava I and Sca I
before ligation.
Discussion
[0107] We have replaced nucleotide sequences within the active site
of the .beta.-lactamase gene with random chemically synthesized DNA
sequences, and selected from a heterogeneous population those
sequences that render E. coli resistant to carbenicillin. The
nucleotide sequence of each of the new mutants has many differences
from that of the parental plasmid and from any natural
.beta.-lactamases so far reported (Bush, 1988; Brenner, 1988;
Kelly, et al., 1980; Spratt & Cromie, 1988; Nicholas &
Strominger, 1988). This supports the notion that the active sites
of enzymes may be more flexible than is generally recognized. As
designed, each of the mutants maintained the codon for Ser-70
present within the oligonucleotide insert. Brenner (1988)
hypothesized that the Ser-70 in .beta.-lactamases evolved from an
ancestral enzyme containing cysteine and, in fact, substitution of
Ser-70 with cysteine yields a .beta.-lactamase with 1-2% of the
activity of the wild type parent (Sigal, et al., 1982). In six out
of the seven mutants we have obtained, the most conserved amino
acid is Pro-67 followed by Thr-71 (four of seven). Even though
Thr-71 is conserved in Class-A .beta.-lactamases, it has been
reported that 14 out of 19 single amino acid replacements at this
site yield active enzyme (Schultz & Richards, 1986). Our
finding that four of the seven random mutants contain codons other
than Thr confirms that threonine is not essential for
catalysis.
[0108] The amino acids within the active site that determine the
substrate specificity of .beta.-lactamase are unknown. The
differences in resistance to .beta.-lactam antibiotics among the
mutants we have obtained suggest that some of the mutants have an
altered substrate specificity (Table 3). The region extending from
Ser-70 to Lys-73 may not be involved in substrate recognition; this
region is conserved in natural .beta.-lactamases that exhibit
differences in substrate specificity (Dale, et al., 1985; Spratt
& Cromie, 1988; Nicholas & Strominger, 1988).
Alternatively, mutations within the region from Pro-66 to Ser-70
may be those responsible for alterations in substrate specificity.
However, this sequence from Ser-70 to Lys-73 may be required for
enzyme stability. In the studies of Schultz and Richards, most--but
not all--substitutions for Thr-71 resulted in decreased activity at
elevated temperatures, and evidence was presented that this
resulted from increased proteolysis (Schultz & Richards, 1986).
We observed a similar thermal lability of mutants selected from the
active-site inserts that contained random nucleotide sequences in
this region. Further studies will be required to determine which
substitutions reduce the stability of the .beta.-lactam resistant
phenotype and if this thermal inactivation results from enzyme
denaturation or increased susceptibility to proteolysis. Most of
the mutants exhibited a greater resistance towards carbenicillin
than the other analogs, particularly at 40' C. (Table 3), and this
could be the result of selection by carbenicillin. Alternatively,
carbenicillin could protect against thermal denaturation by
preferentially binding to .beta.-lactamases; the K.sub.m for
carbenicillin, ampicillin, and benzylpenicillin have been reported
to be 10, 31, and 21 .mu.M, respectively (Labia, et al., 1979).
[0109] This use of random DNA for the generation of new mutants is
based on the hypothesis that multiple amino acid substitutions can
be tolerated within the active sites of enzymes, and that many of
these substitutions could yield enzymes with altered or even new
catalytic activities. Consider a chronology of selective prebiotic
evolutionary events that might offer advantages to sequences with
the best fit. Assume that an average gene was initially coded by
2000 nucleotides and thus was selected for from a reservoir of
4.sup.2000 possible permutations. Early steps in selection could
involve DNA and RNA structure, replication, and transcription
(Orgel, 1986; Eigen & Schuster, 1977). Selections based on
protein structure and specificity of catalysis are likely to be
relatively late events, and might be limited by the interdependence
of metabolic pathways and by the stringencies of protein-protein
interactions in multicomponent systems. A smaller number of
possible permutations would be obtained if genes were assembled in
units on the basis of structural domains (Schultz, et al., 1987;
Savageau, 1986). In either case, as a consequence of progressive
selective processes, a large number of the potential nucleotide
arrangements that were eliminated early in evolution may
nevertheless code for active enzymes.
[0110] The overall frequency of multiple amino acid codon
substitutions in the random collection of 6-lactamase mutants is
much higher than that found in nature. By selecting active genes
from random DNA inserts it might be possible to circumvent the
sequential selective pressures that have occurred during evolution.
Using a series of small random oligonucleotide inserts we should be
able to identify most substitutions that yield reactive molecules
and thus define the topology of the active site on enzymes. Small
changes in the structural configuration at the active site may have
profound influences on the rates and specificities of enzymatic
reactions and/or thermo- and proteolytic stability. New active
sequences selected from random DNA inserts might be able to
catalyze reactions at a rate greater than that of the native
enzymes or might utilize unusual substrates and thus be of
practical importance.
Citations
[0111] Ambler, R. P. (1980) Philos. Trans. R. Soc. London Ser. B
289, 321-331.
[0112] Brenner, S. (1988) Nature 334, 528-530.
[0113] Bush, K. (1988) Rev. Infect. Diseases 10, 681-690.
[0114] Craik, C. S., Largeman, C., Flecher, T., Roczniak, S., Barr,
P. J., Fletterick, R. & Rutter, W. J. (1985) Science 228,
291-297.
[0115] Dalbadie-McFarland, G., Neitzel, J. & Richards, J. H.
(1986) Biochemistry, 25, 332-338.
[0116] Dale, J. W., Godwin, D., Mossakowska, D., Stephenson, P.
& Wall, S. (1985) FEBS Lett. 191, 39-44.
[0117] Eigen, M. & Schuster, P. (1977) Naturwissenschaften, 64,
541-565.
[0118] Hanahan, D. (1983) J. Mol. Biol. 166, 557-580.
[0119] Herzberg, O. & Moult, J. (1987) Science, 236,
694-701.
[0120] Horwitz, M. S. Z. & Loeb, L. A. (1986) Proc. Natl. Acad.
Sci. USA 83, 7405-7409.
[0121] Horwitz, M. S. Z. & Loeb, L. A. (1988a) J. Biol. Chem.,
263, 14724-14731.
[0122] Horwitz, M. S. Z. & Loeb, L. A. (1988b) Science, 241,
703-705.
[0123] Horwitz, M. S. Z., Dube, D. K. & Loeb, L. A. (1989)
Genome in press.
[0124] Kelly, J. A., Dideberg, O., Charlier, P., Wery, J. P.,
Libert, M., Moews, P. C.,
[0125] Knox, J. R., Duez, C., Fraipont, C. L., Joris, B., Dusart,
J., Frere, J. M. & Ghuysen, J. M. (1980) Science, 231,
1429-1431.
[0126] Kobayashi, S., Arai, S., Hayashi, S. & Sakaguchi, T.
(1988) Antimicrob. Agent & Chemo. 32, 1040-1045.
[0127] Labia, R., Barthelemy, M., Fabre, C., Guionie, M. W. &
Peduzzi, J. (1979) IN:
[0128] Beta-Lactamases (Eds., Hamilton-Miller, J. M. T. and Smith,
J. T.), Academic Press, New York, pp. 429-442.
[0129] Maniatis, T., Firtsch, E. F. & Sambrook, J. (1982)
Molecular Cloning: A Laboratory Manual (Cold Spring Harbor
Laboratory, Cold Spring Harbor, NY).
[0130] Mathew, M. & Hedges, R. W. (1976) J. Bacteriol. 125,
713-718.
[0131] Nicholas, R. A. & Strominger, J. L. (1988) Rev. Infect.
Diseases 10, 733-745.
[0132] Oliphant, A. R. & Struhl, K. (1988) Meth. Enzymol. 155,
568-582.
[0133] Orgel, L. L. (1986) J. Theor. Biol., 123, 127-139.
[0134] Perry, L. J. & Wetzel, R. (1984) Science 226,
555-557.
[0135] Sanger, F., Nicklen, S., & Coulson, A. R. (1977) Proc.
Natl. Acad. Sci. USA, 74, 5463-5467.
[0136] Savageau, M. A. (1986) Proc. Natl. Acad. Sci. USA, 83,
1198-1202.
[0137] Schneider, T. D. & Stormo, G. D. (1989) Nucleic Acids
Res., 17, 659-674.
[0138] Schultz, S. C. & Richards, J. H. (1986) Proc. Natl.
Acad. Sci. USA 1588-1592.
[0139] Schultz, S. C., Dalbadie-McFarland, G., Neitzel, J. J. &
Richards, J. (1987) Proteins 2, 290-297.
[0140] Sigal, I. S., Harwood, B. G. & Arentzen, R. (1982) Proc.
Natl. Acad. Sci., USA 79, 7156-7160.
[0141] Spratt, B. G. & Cromie, K. D. (1988) Rev. Infect.
Diseases 10, 699-711.
[0142] While the present invention has been described in
conjunction with the preferred embodiments, one of ordinary skill,
having read the foregoing specification, will be able to effect
various changes, substitutions of equivalents, and alterations to
the methods set forth herein. It is therefore intended that the
protection granted by Letters Patent hereon be limited only by the
appended claims and equivalents thereof.
* * * * *